Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 2/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 11/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 11/20 | 0.44 |
| ▸ | CLK4 | Q9HAZ1 | 11/20 | 0.44 |
| ▸ | USP2 | O75604 | 9/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 9/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 7/20 | 0.44 |
| ▸ | LMNA | P02545 | 4/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | TSHR | P16473 | 6/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.44 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.43 |
| ▸ | RECQL | P46063 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | USP10 | Q14694 | 1/20 | 0.41 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6364148 | 0.81 | ALDH1A1 (0.60) | EGFRLMNAALDH1A1KMT2AHSD17B10 | |
| SCHEMBL6369394 | 0.75 | CYP1A2 (0.42) | EGFRCYP1A2CYP3A4CLK4USP2 | |
| SCHEMBL7975392 | 0.70 | EGFR (0.73) | EGFRHIF1AMAPK1 | |
| SCHEMBL20840381 | 0.68 | CYP1A2 (0.52) | EGFRCYP1A2LMNAALDH1A1KMT2A | |
| SCHEMBL30991002 | 0.68 | CYP1A2 (0.52) | EGFRCYP1A2LMNAALDH1A1KMT2A | |
| SCHEMBL8491540 | 0.68 | HTT (0.60) | EGFRLMNATSHRKMT2AHIF1A | |
| SCHEMBL24674289 | 0.68 | USP10 (0.46) | EGFRCYP1A2CYP3A4CLK4USP2 | |
| SCHEMBL29427593 | 0.68 | USP10 (0.46) | EGFRCYP1A2CYP3A4CLK4USP2 | |
| SCHEMBL22714261 | 0.68 | CYP1A2 (0.46) | EGFRCYP1A2CYP3A4CLK4USP2 | |
| SCHEMBL29427698 | 0.68 | CYP1A2 (0.46) | EGFRCYP1A2CYP3A4CLK4USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2005016925-A1 | AZAQUINAZOLINE DERIVATIVES | PFIZER LIMITED (GB) | 2005-02-24 | — | — | WO | disclosed |
| US-20050038047-A1 | Azaquinazoline derivatives | EDWARDS PAUL JOHN (GB) | 2005-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050038047-A1 | Azaquinazoline derivatives | AZI2, P2RX5, P2RX7 | EGFR 4865/4885CYP1A2 155/4885CYP3A4 132/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.